Y mAbs Therapeutics

Company Profile

Y mAbs Therapeutics had its IPO on 2018-09-21 under the ticker symbol YMAB.

The company operates in the Healthcare sector and Biotechnology industry. Y mAbs Therapeutics has a staff strength of 147 employees.

Stock update

Shares of Y mAbs Therapeutics opened at $7.92 at the start of the last trading session i.e. 2023-06-03.

The stocks traded within a range of $7.56 - $8.18, and closed at $8.17.

This is a +5.01% increase from the previous day's closing price.

A total volume of 274,600 shares were traded at the close of the day’s session.

In the last one week, shares of Y mAbs Therapeutics have slipped by -15.07%.

Y mAbs Therapeutics's Key Ratios

Y mAbs Therapeutics has a market cap of $356.85 million, indicating a price to book ratio of 2.056 and a price to sales ratio of 5.2098.

In the last 12-months Y mAbs Therapeutics’s revenue was $75.03 million with a gross profit of $57.70 million and an EBITDA of $-57817000. The EBITDA ratio measures Y mAbs Therapeutics's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Y mAbs Therapeutics’s operating margin was -78.16% while its return on assets stood at -22.32% with a return of equity of -55.7%.

In Q1, Y mAbs Therapeutics’s quarterly earnings growth was a positive 0% while revenue growth was a positive 93.1%.

Y mAbs Therapeutics’s PE and PEG Ratio

Forward PE

119.0476

Trailing PE

0

PEG

Its diluted EPS in the last 12-months stands at $-1.6 per share while it has a forward price to earnings multiple of 119.0476 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Y mAbs Therapeutics’s profitability.

Y mAbs Therapeutics stock is trading at a EV to sales ratio of 2.5226 and a EV to EBITDA ratio of -0.8522. Its price to sales ratio in the trailing 12-months stood at 5.2098.

Y mAbs Therapeutics stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets

$137.45 million

Total Liabilities

$25.92 million

Operating Cash Flow

$0

Capital Expenditure

$0

Dividend Payout Ratio

0%

Y mAbs Therapeutics ended 2023 with $137.45 million in total assets and $0 in total liabilities. Its intangible assets were valued at $137.45 million while shareholder equity stood at $107.83 million.

Y mAbs Therapeutics ended 2023 with $0 in deferred long-term liabilities, $25.92 million in other current liabilities, 4000.00 in common stock, $-442433000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $92.63 million and cash and short-term investments were $92.63 million. The company’s total short-term debt was $855,000 while long-term debt stood at $0.

Y mAbs Therapeutics’s total current assets stands at $124.01 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $18.70 million compared to accounts payable of $8.84 million and inventory worth $8.95 million.

In 2023, Y mAbs Therapeutics's operating cash flow was $0 while its capital expenditure stood at $0.

Comparatively, Y mAbs Therapeutics paid $0 in dividends in 2023.

Other key metrics

Current Trading Price

$8.17

52-Week High

$20.48

52-Week Low

$2.7

Analyst Target Price

$12.71

Y mAbs Therapeutics stock is currently trading at $8.17 per share. It touched a 52-week high of $20.48 and a 52-week low of $20.48. Analysts tracking the stock have a 12-month average target price of $12.71.

Its 50-day moving average was $6.85 and 200-day moving average was $7.63 The short ratio stood at 3.99 indicating a short percent outstanding of 0%.

Around 1234.3% of the company’s stock are held by insiders while 6180.8% are held by institutions.